Similar articles for PMID: 9111538

Year	Number of Results
1945	1
1946	1
1947	1
1948	1
1952	1
1961	1
1965	3
1966	1
1967	2
1969	1
1970	3
1971	1
1972	2
1973	2
1974	1
1975	2
1976	2
1977	4
1978	3
1980	1
1981	2
1982	1
1983	2
1984	4
1985	2
1987	1
1988	4
1989	3
1990	6
1991	9
1992	7
1993	8
1994	5
1995	11
1996	10
1997	5
1998	2
1999	8
2000	2
2001	4
2002	2
2003	2
2004	1
2005	6
2006	5
2007	3
2008	3
2009	6
2010	5
2011	1
2012	5
2013	9
2014	3
2015	12
2016	12
2017	14
2018	13
2019	13
2020	9
2021	21
2022	24
2023	10
2024	0

1

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB. Cohen D, et al. Lancet. 1997 Jan 18;349(9046):155-9. doi: 10.1016/S0140-6736(96)06255-1. Lancet. 1997. PMID: 9111538 Clinical Trial.

2

Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.

Robin G, Keisari Y, Slepon R, Ashkenazi S, Cohen D. Robin G, et al. Vaccine. 1999 Aug 6;17(23-24):3109-15. doi: 10.1016/s0264-410x(99)00136-x. Vaccine. 1999. PMID: 10462247 Clinical Trial.

3

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.

Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R; Israel Shigella Study Group. Passwell JH, et al. Pediatr Infect Dis J. 2003 Aug;22(8):701-6. doi: 10.1097/01.inf.0000078156.03697.a5. Pediatr Infect Dis J. 2003. PMID: 12913770 Clinical Trial.

4

Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.

Cohen D, Ashkenazi S, Schneerson R, Farzam N, Bialik A, Meron-Sudai S, Asato V, Goren S, Baran TZ, Muhsen K, Gilbert PB, MacLennan CA. Cohen D, et al. Clin Microbiol Infect. 2023 Mar;29(3):366-371. doi: 10.1016/j.cmi.2022.10.011. Epub 2022 Oct 13. Clin Microbiol Infect. 2023. PMID: 36243351 Free PMC article. Clinical Trial.

5

Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, Orr N, Taylor DN, Sadoff JC, Chu C, Shiloach J, Schneerson R, Robbins JB. Cohen D, et al. Infect Immun. 1996 Oct;64(10):4074-7. doi: 10.1128/iai.64.10.4074-4077.1996. Infect Immun. 1996. PMID: 8926071 Free PMC article. Clinical Trial.

6

Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.

Cohen D, Orr N, Robin G, Slepon R, Ashkenazi S, Ashkenazi I, Shemer J. Cohen D, et al. Clin Diagn Lab Immunol. 1996 Jul;3(4):451-5. doi: 10.1128/cdli.3.4.451-455.1996. Clin Diagn Lab Immunol. 1996. PMID: 8807212 Free PMC article.

7

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.

Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG. Talaat KR, et al. EBioMedicine. 2021 Apr;66:103310. doi: 10.1016/j.ebiom.2021.103310. Epub 2021 Apr 13. EBioMedicine. 2021. PMID: 33862589 Free PMC article. Clinical Trial.

8

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.

Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, Roberson R, Robbins JB, Schneerson R. Passwell JH, et al. Infect Immun. 2001 Mar;69(3):1351-7. doi: 10.1128/IAI.69.3.1351-1357.2001. Infect Immun. 2001. PMID: 11179298 Free PMC article. Clinical Trial.

9

Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.

Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R. Ashkenazi S, et al. J Infect Dis. 1999 Jun;179(6):1565-8. doi: 10.1086/314759. J Infect Dis. 1999. PMID: 10228084 Clinical Trial.

10

Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.

Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon ML, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A. Cohen D, et al. Lancet Infect Dis. 2021 Apr;21(4):546-558. doi: 10.1016/S1473-3099(20)30488-6. Epub 2020 Nov 10. Lancet Infect Dis. 2021. PMID: 33186516 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

294 results

Results by year